Coherus Oncology, Inc. (CHRS) P/E Ratio History
Historical price-to-earnings valuation from 2019 to 2024
Loading P/E history...
CHRS Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Coherus Oncology, Inc. (CHRS) trades at a price-to-earnings ratio of 1.2x, with a stock price of $1.76 and trailing twelve-month earnings per share of $1.40.
The current P/E is 87% below its 5-year average of 9.8x. Over the past five years, CHRS's P/E has ranged from a low of 7.6x to a high of 15.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, CHRS trades at a 94% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, CHRS trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CHRS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CHRS P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 62.4 | -Best | +158% | |
| $2B | 60.5 | -Best | -63% | |
| $7B | 15.5Lowest | -Best | +1747%Best | |
| $15B | 42.5 | -Best | -22% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
CHRS Historical P/E Data (2019–2024)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2024 Q4 | $1.38 | $0.18 | 7.8x | -20% | |
| FY2020 Q4 | $17.38 | $1.63 | 10.7x | +9% | |
| FY2020 Q3 | Wed Sep 30 2020 00:00:00 GM | $18.34 | $2.04 | 9.0x | -8% |
| FY2020 Q2 | $17.86 | $2.34 | 7.6x | -22% | |
| FY2020 Q1 | $16.22 | $1.96 | 8.3x | -15% | |
| FY2019 Q4 | $18.00 | $1.19 | 15.1x | +55% |
Average P/E for displayed period: 9.8x
See CHRS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CHRS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CHRS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCHRS — Frequently Asked Questions
Quick answers to the most common questions about buying CHRS stock.
Is CHRS stock overvalued or undervalued?
CHRS trades at 1.2x P/E, below its 5-year average of 9.8x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does CHRS's valuation compare to peers?
Coherus Oncology, Inc. P/E of 1.2x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is CHRS's PEG ratio?
CHRS PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2019-2024.